Healthy Skepticism Library Topics: Marketing

Marketing

This page lists 45 references in the Main Healthy Skepticism Library relevant to Marketing.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.

HSL6902
Eichacker PQ, Natanson C, Danner RL.
Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
N Engl J Med 2006 Oct 19;355(16):1640-2
http://content.nejm.org/cgi/content/full/355/16/1640

HSL6000
Musacchio R, Hunkler R
More Than a Game of Keep Away
Pharmaceutical Executive 2006 Jul 7
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=323311

HSL6152
Day M.
International consumer group slates drug companies' marketing practices.
BMJ 2006 Jul 1;333(7557):14
http://bmj.bmjjournals.com/cgi/content/full/333/7557/14-b

HSL6148
Lanier WL.
Editor's note: Industry support of articles published in Mayo Clinic Proceedings.
Mayo Clin Proc 2006 Jun 01;81(6):851-2

HSL5126
Dyer O.
Watchdog gives spoof awards for aggressive marketing of drugs.
BMJ 2006 May 6;332(7549):1050
http://bmj.bmjjournals.com/cgi/content/full/332/7549/1050-a

HSL2681
Zoutman D E, Ford BD, Bassili AR
Prescription data
Canadian Medical Association Journal 2006 May 01;164(10):1410-1409

HSL6620
Kids are different.
Profiles Healthc Commun 2006 May-Jun 01;22(3):20-4,

HSL6105
Grace M.
Ethical marketing.
Br Dent J 2006 Apr 22;200(8):418
http://www.nature.com/doifinder/10.1038/sj.bdj.4813532

HSL5648
Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R.
Conflict of interest.
Am J Psychiatry 2006 Apr;163(4):571-3
http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=16585427

HSL5361
Anderson JC, Narus JA, van Rossum W.
Customer value propositions in business markets.
Harv Bus Rev 2006 Mar 01;84(3):90-9,

HSL5384
Atkinson M, Bevan R, Becker S, Breitz L, Brennan P, Crisp J, Etherton C, Ellis R, Feran K, Frazer E, Freiburger P, Garber K, Geekie M, Giedrys-Leeper E, Greenwall L, Grundy B, Heffernan M, Hetherington I, Hill G, Kidd A, Moxham D, Olesen N, Paolella T, Ro
Commercialism in marketing.
Br Dent J 2006 Feb 11;200(3):124-5
Link to source with long URL

HSL5306
Nystrand A.
[The examples Cancer Foundation, Heart-Lung foundation and Child Cancer Foundation: aggressive marketing undermines confidence].
Lakartidningen 2006 Feb 1-7;103(5):306-7

HSL6652
Manley PA.
Communicate first.
Mark Health Serv 2006 Sum;26(2):42

HSL2670
Roner L
Operationalized measurement of marketing programs
eyeforpharma Briefing 2005 Aug 17(151)
http://www.eyeforpharma.com/index.asp?nli=o&g-p&nld=8/17/2005&news=47332

HSL670
The global pharmceutical industry
College Journal (Wall St Times) 2005 Mar
Link to source with long URL

HSL6576
Menighan TE.
Systems-based approach to risk management.
J Am Pharm Assoc (Wash DC) 2005 Mar-Apr 01;45(2):116

HSL5092
Oldani MJ.
Thick prescriptions: toward an interpretation of pharmaceutical sales practices.
Med Anthropol Q 2004 Sep;18(3):325-56

HSL294
Ford N, Wilson D, Bunjumnong O, von Schoen Angerer T.
The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Lancet 2004 Feb 14;363(9408):560-3
Link to source with long URL

HSL1460
Carter T.
Pfizer and its competitive marketing challenges.
J Hosp Mark Public Relations 2003;14(2):85-97

HSL2230
Potts M.
Two pills, two paths: a tale of gender bias.
Endeavour 2003;27(3):127-30

HSL2396
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books; 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html

HSL2298
Pinkus RL.
From Lydia Pinkham to Bob Dole: what the changing face of direct-to-consumer drug advertising reveals about the professionalism of medicine.
Kennedy Inst Ethics J 2002 Jun;12(2):141-58
Link to source with long URL

HSL2294
Rao SK.
Pharmaceutical marketing in a new age, Effective campaigns still need to focus on what customers want.
Mark Health Serv 2002 Spring;22(1):6-12

HSL2255
Syrycki M.
[Adaptation possibility of chosen aspects of pharmaceutical marketing for realization of promotion in health care]
Wiad Lek. 2002;55(Suppl 1):482-8
Link to source with long URL

HSL2894
Carter T.
What can Johnson & Johnson do to remain a giant in the health care industry?
J Hosp Mark Public Relations 2002;14(1):93-103
Link to source with long URL

HSL2895
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20
Link to source with long URL

HSL2682
Zitner D.
Prescription data
Canadian Medical Association Journal 2001 May 15;164(10):1408-1409

HSL2697
Short , S .
Prescription data
CMAG 2001 May 15;164(10):1408

HSL2701
Korman , R .
Prescription data
CMAJ 2001 May 15;164(10):1408

HSL123
Robinson J.
Prescription games: money, ego, and power inside the global pharmaceutical industry
Toronto: McClelland and Stewart; 2001
Link to source with long URL

HSL362
Angell M.
The pharmaceutical industry--to whom is it accountable
N Engl J Med 2000;342:1902-1904
http://content.nejm.org/cgi/content/extract/342/25/1902

HSL4805
Cearnal ME.
Medical marketing communications today: Use and abuse
Journal of Pharmaceutical Marketing & Management 1992;7(1):23-32

HSL4670
Johnson JE.
Of mugs and marketing [1st of 3 letters]
JAMA 1991;266(20):2830

HSL4671
Kelly MJ.
Of mugs and marketing [3rd of 3 letters]
JAMA 1991;266(20):2830

HSL4673
Kirkland LR.
Of mugs and marketing [2nd of 3 letters]
JAMA 1991;266(20):2830

HSL4697
Rennie D.
Of mugs and marketing [2nd of 2 replies]
JAMA 1991;266(20):2831

HSL4747
Kallir J.
Déja vu all over again
Medical Marketing & Media 1991;26(6):42

HSL4129
Brickler EM.
Industrial marketing and medical ethics
New England Journal of Medicine 1989;320:1690-1692

HSL4007
Hurwitz MA, Caves RE.
Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals
Journal of Law and Economics 1988;31:299-320

HSL3869
Buckley EG.
Post-marketing surveillance of new drugs.
J R Coll Gen Pract 1987 Aug;37(301):337-8

HSL3918
Spitzer WO, Hutchinson T, Lane D.
Postmarketing management of drug use: toward rational public policy.
CMAJ 1987 May 15;136(10):1022-4

HSL3963
Piroxicam
1987 May:1-7

HSL3904
Lidstone J.
Marketing planning for the pharmaceutical industry
1987

HSL3723
Mackowiak JI, Gagnon JP.
Effects of promotion on pharmaceutical demand.
Soc Sci Med 1985;20(11):1191-7

HSL3280
Telser L, Best W, Egan JW, Higinbotham HN.
The theory of supply with applications to the ethical pharmaceutical industry
Journal of Law and Economics 1975;18:449-478

		Healthy Skepticism Countering misleading drug promotion Home \| About us \| Site info \| Contact us \| Links \| Other What's new \| AdWatch \| HS Int News \| Library \| Fora
Home - www.healthyskepticism.org > library > topics: marketing : Updated 23 August, 2005
For you Free Updates Can we help you? Help the cause Join in Subscribe to Healthy Skepticism Updates Feedback If you like our work please tell others. If not, please tell us.		Marketing This page lists 45 references in the Main Healthy Skepticism Library relevant to Marketing. Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text. HSL6902 Eichacker PQ, Natanson C, Danner RL. Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006 Oct 19;355(16):1640-2 http://content.nejm.org/cgi/content/full/355/16/1640 HSL6000 Musacchio R, Hunkler R More Than a Game of Keep Away Pharmaceutical Executive 2006 Jul 7 http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=323311 HSL6152 Day M. International consumer group slates drug companies' marketing practices. BMJ 2006 Jul 1;333(7557):14 http://bmj.bmjjournals.com/cgi/content/full/333/7557/14-b HSL6148 Lanier WL. Editor's note: Industry support of articles published in Mayo Clinic Proceedings. Mayo Clin Proc 2006 Jun 01;81(6):851-2 HSL5126 Dyer O. Watchdog gives spoof awards for aggressive marketing of drugs. BMJ 2006 May 6;332(7549):1050 http://bmj.bmjjournals.com/cgi/content/full/332/7549/1050-a HSL2681 Zoutman D E, Ford BD, Bassili AR Prescription data Canadian Medical Association Journal 2006 May 01;164(10):1410-1409 HSL6620 Kids are different. Profiles Healthc Commun 2006 May-Jun 01;22(3):20-4, HSL6105 Grace M. Ethical marketing. Br Dent J 2006 Apr 22;200(8):418 http://www.nature.com/doifinder/10.1038/sj.bdj.4813532 HSL5648 Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R. Conflict of interest. Am J Psychiatry 2006 Apr;163(4):571-3 http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=16585427 HSL5361 Anderson JC, Narus JA, van Rossum W. Customer value propositions in business markets. Harv Bus Rev 2006 Mar 01;84(3):90-9, HSL5384 Atkinson M, Bevan R, Becker S, Breitz L, Brennan P, Crisp J, Etherton C, Ellis R, Feran K, Frazer E, Freiburger P, Garber K, Geekie M, Giedrys-Leeper E, Greenwall L, Grundy B, Heffernan M, Hetherington I, Hill G, Kidd A, Moxham D, Olesen N, Paolella T, Ro Commercialism in marketing. Br Dent J 2006 Feb 11;200(3):124-5 Link to source with long URL HSL5306 Nystrand A. [The examples Cancer Foundation, Heart-Lung foundation and Child Cancer Foundation: aggressive marketing undermines confidence]. Lakartidningen 2006 Feb 1-7;103(5):306-7 HSL6652 Manley PA. Communicate first. Mark Health Serv 2006 Sum;26(2):42 HSL2670 Roner L Operationalized measurement of marketing programs eyeforpharma Briefing 2005 Aug 17(151) http://www.eyeforpharma.com/index.asp?nli=o&g-p&nld=8/17/2005&news=47332 HSL670 The global pharmceutical industry College Journal (Wall St Times) 2005 Mar Link to source with long URL HSL6576 Menighan TE. Systems-based approach to risk management. J Am Pharm Assoc (Wash DC) 2005 Mar-Apr 01;45(2):116 HSL5092 Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q 2004 Sep;18(3):325-56 HSL294 Ford N, Wilson D, Bunjumnong O, von Schoen Angerer T. The role of civil society in protecting public health over commercial interests: lessons from Thailand. Lancet 2004 Feb 14;363(9408):560-3 Link to source with long URL HSL1460 Carter T. Pfizer and its competitive marketing challenges. J Hosp Mark Public Relations 2003;14(2):85-97 HSL2230 Potts M. Two pills, two paths: a tale of gender bias. Endeavour 2003;27(3):127-30 HSL2396 Kay J. The Truth about Markets: Why Some Nations are Rich but Most Remain Poor London: Penguin Books; 2003 http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html HSL2298 Pinkus RL. From Lydia Pinkham to Bob Dole: what the changing face of direct-to-consumer drug advertising reveals about the professionalism of medicine. Kennedy Inst Ethics J 2002 Jun;12(2):141-58 Link to source with long URL HSL2294 Rao SK. Pharmaceutical marketing in a new age, Effective campaigns still need to focus on what customers want. Mark Health Serv 2002 Spring;22(1):6-12 HSL2255 Syrycki M. [Adaptation possibility of chosen aspects of pharmaceutical marketing for realization of promotion in health care] Wiad Lek. 2002;55(Suppl 1):482-8 Link to source with long URL HSL2894 Carter T. What can Johnson & Johnson do to remain a giant in the health care industry? J Hosp Mark Public Relations 2002;14(1):93-103 Link to source with long URL HSL2895 Calfee JE. The role of marketing in pharmaceutical research and development. Pharmacoeconomics 2002;20 Link to source with long URL HSL2682 Zitner D. Prescription data Canadian Medical Association Journal 2001 May 15;164(10):1408-1409 HSL2697 Short , S . Prescription data CMAG 2001 May 15;164(10):1408 HSL2701 Korman , R . Prescription data CMAJ 2001 May 15;164(10):1408 HSL123 Robinson J. Prescription games: money, ego, and power inside the global pharmaceutical industry Toronto: McClelland and Stewart; 2001 Link to source with long URL HSL362 Angell M. The pharmaceutical industry--to whom is it accountable N Engl J Med 2000;342:1902-1904 http://content.nejm.org/cgi/content/extract/342/25/1902 HSL4805 Cearnal ME. Medical marketing communications today: Use and abuse Journal of Pharmaceutical Marketing & Management 1992;7(1):23-32 HSL4670 Johnson JE. Of mugs and marketing [1st of 3 letters] JAMA 1991;266(20):2830 HSL4671 Kelly MJ. Of mugs and marketing [3rd of 3 letters] JAMA 1991;266(20):2830 HSL4673 Kirkland LR. Of mugs and marketing [2nd of 3 letters] JAMA 1991;266(20):2830 HSL4697 Rennie D. Of mugs and marketing [2nd of 2 replies] JAMA 1991;266(20):2831 HSL4747 Kallir J. Déja vu all over again Medical Marketing & Media 1991;26(6):42 HSL4129 Brickler EM. Industrial marketing and medical ethics New England Journal of Medicine 1989;320:1690-1692 HSL4007 Hurwitz MA, Caves RE. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals Journal of Law and Economics 1988;31:299-320 HSL3869 Buckley EG. Post-marketing surveillance of new drugs. J R Coll Gen Pract 1987 Aug;37(301):337-8 HSL3918 Spitzer WO, Hutchinson T, Lane D. Postmarketing management of drug use: toward rational public policy. CMAJ 1987 May 15;136(10):1022-4 HSL3963 Piroxicam 1987 May:1-7 HSL3904 Lidstone J. Marketing planning for the pharmaceutical industry 1987 HSL3723 Mackowiak JI, Gagnon JP. Effects of promotion on pharmaceutical demand. Soc Sci Med 1985;20(11):1191-7 HSL3280 Telser L, Best W, Egan JW, Higinbotham HN. The theory of supply with applications to the ethical pharmaceutical industry Journal of Law and Economics 1975;18:449-478
821 visits to this page since 1 January 2007		Home \| Add to Favourites \| Site Map \| Credits \| Privacy Policy \| Update Policy \| Feedback Policy

Countering misleading drug promotion

Marketing